Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) 的整體財務健康評級為 B+ 綜合評分為 0 （滿分5分）.
這表明公司面臨一些值得關注的財務挑戰. 評級截至 2026-03-18.
| 日期 | 評級 | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-01-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
